{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:04:11Z","timestamp":1794607451163,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82403190"],"award-info":[{"award-number":["82403190"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82372770"],"award-info":[{"award-number":["82372770"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Yishan Research Project of Jiangsu Cancer Hospital","award":["YSZD202406"],"award-info":[{"award-number":["YSZD202406"]}]},{"DOI":"10.13039\/501100004610","name":"Science and Technology Support Program of Jiangsu Province","doi-asserted-by":"publisher","award":["BG2024026"],"award-info":[{"award-number":["BG2024026"]}],"id":[{"id":"10.13039\/501100004610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"crossref","award":["2024ZD0524000"],"award-info":[{"award-number":["2024ZD0524000"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epidermal growth factor receptor (EGFR), characterized by its high positivity rate and strong specificity in triple-negative breast cancer (TNBC), has long been recognized as one of the characteristics of this subtype. However, EGFR inhibitors have demonstrated limited clinical efficacy in TNBC treatments. Previous studies revealed that multiple receptor tyrosine kinases (RTKs) were activated in TNBC. These RTKs cooperate through dimerization to activate downstream pathway phosphorylation, rendering EGFR monotherapy ineffective. This highlights the necessity for combinatorial strategies targeting multiple RTKs to treat TNBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Published bulk-RNA sequencing datasets from erlotinib resistant TNBC patient-derived xenografts model revealed changes in gene sets in erlotinib resistant tissues. RNA immunoprecipitation and methylated RNA immunoprecipitation sequencing were used to detect co-regulated RTKs by insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3). RNA pull-down and molecular docking clarified the interaction sites between IGF2BP3 and RTKs. Computational virtual docking, hierarchical screening, microscale thermophoresis and cytotoxicity assays were employed to screen small-molecule inhibitors aimed at disrupting IGF2BP3-RTK interactions. The determination of drug synergistic effects was achieved through the calculation of the combination index.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this study, we identified IGF2BP3 could coordinately regulate multiple RTKs\u2019 mRNA through an m6A-dependent manner and activate RTKs expression, and thus could be the key point to address the drug resistance problem. After clarifying the interaction sites between IGF2BP3 protein and RTK mRNAs, we identified cynaroside, a small-molecule inhibitor capable of disrupting IGF2BP3-RTK interactions, as a promising enhancer of tyrosine kinase inhibitor (TKI) efficacy. Moreover, we proposed a novel therapeutic strategy by combining cynaroside with TKI and chose the EGFR\/MET bispecific antibody amivantamab for the best candidate in TNBC target treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study provide a mechanistic insight into IGF2BP3-mediated EGFR inhibitor resistance and present an emerging combinatorial approach to overcome therapeutic limitations in TNBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03686-7","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:55:13Z","timestamp":1773212113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Combinatorial inhibition of IGF2BP3-regulated receptor tyrosine kinases offers a new therapeutic strategy for triple-negative breast cancer"],"prefix":"10.1186","volume":"45","author":[{"given":"Zi-Wen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Yuan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yi","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Fu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"1","key":"3686_CR1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","volume":"16","author":"S Zhu","year":"2023","unstructured":"Zhu S, et al. Recent advances in targeted strategies for triple-negative breast cancer. J Hematol Oncol. 2023;16(1):100.","journal-title":"J Hematol Oncol"},{"key":"3686_CR2","doi-asserted-by":"publisher","first-page":"e071674","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023;381:e071674.","journal-title":"BMJ"},{"issue":"8","key":"3686_CR3","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","volume":"186","author":"E Nolan","year":"2023","unstructured":"Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell. 2023;186(8):1708\u201328.","journal-title":"Cell"},{"issue":"5","key":"3686_CR4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41575-022-00736-1","volume":"20","author":"H Bando","year":"2023","unstructured":"Bando H, Ohtsu A, Yoshino T. Therapeutic landscape and future direction of metastatic colorectal cancer. Nat Rev Gastroenterol Hepatol. 2023;20(5):306\u201322.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10212","key":"3686_CR5","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet (London England). 2019;394(10212):1915\u201328.","journal-title":"Lancet (London England)"},{"issue":"1","key":"3686_CR6","first-page":"44","volume":"388","author":"R Yaeger","year":"2023","unstructured":"Yaeger R, et al. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. The New England. J Med. 2023;388(1):44\u201354.","journal-title":"J Med"},{"key":"3686_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ctrv.2016.12.010","volume":"53","author":"R Costa","year":"2017","unstructured":"Costa R, et al. Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. Cancer Treat Rev. 2017;53:111\u20139.","journal-title":"Cancer Treat Rev"},{"issue":"21","key":"3686_CR8","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1200\/JCO.2010.34.5579","volume":"30","author":"LA Carey","year":"2012","unstructured":"Carey LA, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2012;30(21):2615\u201323.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"3","key":"3686_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41568-020-00322-0","volume":"21","author":"S Kumagai","year":"2021","unstructured":"Kumagai S, Koyama S, Nishikawa H. Antitumour immunity regulated by aberrant ERBB family signalling. Nat Rev Cancer. 2021;21(3):181\u201397.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"3686_CR10","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1002\/ijc.30242","volume":"139","author":"S Ellebaek","year":"2016","unstructured":"Ellebaek S, et al. Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers. Int J Cancer. 2016;139(9):2095\u2013105.","journal-title":"Int J Cancer"},{"issue":"1","key":"3686_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40779-024-00582-z","volume":"11","author":"K Mehta","year":"2024","unstructured":"Mehta K, et al. Targeting RTKs\/nRTKs as promising therapeutic strategies for the treatment of triple-negative breast cancer: evidence from clinical trials. Military Med Res. 2024;11(1):76.","journal-title":"Military Med Res"},{"issue":"8","key":"3686_CR12","first-page":"1609","volume":"6","author":"K Nakai","year":"2016","unstructured":"Nakai K, Hung M-C, Yamaguchi H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res. 2016;6(8):1609\u201323.","journal-title":"Am J Cancer Res"},{"key":"3686_CR13","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61\u201370.","DOI":"10.1038\/nature11412"},{"key":"3686_CR14","doi-asserted-by":"publisher","first-page":"102436","DOI":"10.1016\/j.ctrv.2022.102436","volume":"109","author":"JZ Drago","year":"2022","unstructured":"Drago JZ, et al. Beyond HER2: targeting the ErbB receptor family in breast cancer. Cancer Treat Rev. 2022;109:102436.","journal-title":"Cancer Treat Rev"},{"issue":"13","key":"3686_CR15","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-22-3059","volume":"83","author":"Z Lin","year":"2023","unstructured":"Lin Z, et al. Metabolic reprogramming driven by IGF2BP3 promotes acquired resistance to EGFR inhibitors in non-small cell lung cancer. Cancer Res. 2023;83(13):2187\u2013207.","journal-title":"Cancer Res"},{"issue":"1","key":"3686_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrm.2016.132","volume":"18","author":"BS Zhao","year":"2017","unstructured":"Zhao BS, Roundtree IA, He C. Post-transcriptional gene regulation by mRNA modifications. Nat Rev Mol Cell Biol. 2017;18(1):31\u201342.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"3686_CR17","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41580-023-00622-x","volume":"24","author":"H Sun","year":"2023","unstructured":"Sun H, et al. Regulation and functions of non-m6A mRNA modifications. Nat Rev Mol Cell Biol. 2023;24(10):714\u201331.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"3686_CR18","doi-asserted-by":"publisher","first-page":"e1427","DOI":"10.1002\/ctm2.1427","volume":"13","author":"X Zhang","year":"2023","unstructured":"Zhang X, et al. IGF2BP3 mediates the mRNA degradation of NF1 to promote triple-negative breast cancer progression via an m6A-dependent manner. Clin Translational Med. 2023;13(9):e1427.","journal-title":"Clin Translational Med"},{"key":"3686_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.canlet.2017.11.039","volume":"415","author":"H-Y Kim","year":"2018","unstructured":"Kim H-Y, Ha Thi HT, Hong S. IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor. Cancer Lett. 2018;415:30\u20139.","journal-title":"Cancer Lett"},{"issue":"9","key":"3686_CR20","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/onc.2015.164","volume":"35","author":"S Samanta","year":"2016","unstructured":"Samanta S, et al. IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG. Oncogene. 2016;35(9):1111\u201321.","journal-title":"Oncogene"},{"issue":"3","key":"3686_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41556-018-0045-z","volume":"20","author":"H Huang","year":"2018","unstructured":"Huang H, et al. Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20(3):285\u201395.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"3686_CR22","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41467-019-09769-8","volume":"10","author":"T Schneider","year":"2019","unstructured":"Schneider T, et al. Combinatorial recognition of clustered RNA elements by the multidomain RNA-binding protein IMP3. Nat Commun. 2019;10(1):2266.","journal-title":"Nat Commun"},{"issue":"1","key":"3686_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12964-025-02316-7","volume":"23","author":"Z-W Wang","year":"2025","unstructured":"Wang Z-W, et al. IGF2BP3 promotes autophagy-mediated TNBC metastasis via m6A-dependent, cap-independent c-Met translation. Cell Communication Signaling: CCS. 2025;23(1):303.","journal-title":"Cell Communication Signaling: CCS"},{"issue":"8","key":"3686_CR24","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","volume":"10","author":"J Yun","year":"2020","unstructured":"Yun J, et al. Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR Exon 20 insertion-driven NSCLC. Cancer Discov. 2020;10(8):1194\u2013209.","journal-title":"Cancer Discov"},{"issue":"1","key":"3686_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12943-024-02150-4","volume":"23","author":"J-H Kang","year":"2024","unstructured":"Kang J-H, et al. Tumor-intrinsic role of ICAM-1 in driving metastatic progression of triple-negative breast cancer through direct interaction with EGFR. Mol Cancer. 2024;23(1):230.","journal-title":"Mol Cancer"},{"issue":"6","key":"3686_CR26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41419-018-0691-x","volume":"9","author":"A Yallowitz","year":"2018","unstructured":"Yallowitz A, et al. Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells. Cell Death Dis. 2018;9(6):621.","journal-title":"Cell Death Dis"},{"issue":"3","key":"3686_CR27","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1158\/2159-8290.CD-12-0012","volume":"2","author":"LA Garraway","year":"2012","unstructured":"Garraway LA, J\u00e4nne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2012;2(3):214\u201326.","journal-title":"Cancer Discov"},{"issue":"11","key":"3686_CR28","doi-asserted-by":"publisher","first-page":"e22618","DOI":"10.1096\/fj.202200751RR","volume":"36","author":"T Jiang","year":"2022","unstructured":"Jiang T, et al. RNA m6A reader IGF2BP3 promotes metastasis of triple-negative breast cancer via SLIT2 repression. FASEB Journal: Official Publication Federation Am Soc Experimental Biology. 2022;36(11):e22618.","journal-title":"FASEB Journal: Official Publication Federation Am Soc Experimental Biology"},{"key":"3686_CR29","doi-asserted-by":"crossref","unstructured":"Cai M-Y et al. Dual Regulation of FZD1\/7 by IGF2BP3 Enhances Stem-like Properties and Carboplatin Resistance in Triple-Negative Breast Cancer. Cancer Letters, 2025: p. 217944.","DOI":"10.1016\/j.canlet.2025.217944"},{"issue":"9","key":"3686_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41419-023-06099-y","volume":"14","author":"L-J Chen","year":"2023","unstructured":"Chen L-J, et al. IGF2BP3 promotes the progression of colorectal cancer and mediates cetuximab resistance by stabilizing EGFR mRNA in an m6A-dependent manner. Cell Death Dis. 2023;14(9):581.","journal-title":"Cell Death Dis"},{"key":"3686_CR31","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fendo.2018.00178","volume":"9","author":"C Mancarella","year":"2018","unstructured":"Mancarella C, et al. Insulin-like growth factor 2 mRNA-binding protein 3 influences sensitivity to Anti-IGF system agents through the translational regulation of IGF1R. Front Endocrinol. 2018;9:178.","journal-title":"Front Endocrinol"},{"key":"3686_CR32","doi-asserted-by":"crossref","unstructured":"Lederer M et al. The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer. Sem Cancer Biol. 2014;29:3\u201312.","DOI":"10.1016\/j.semcancer.2014.07.006"},{"issue":"6","key":"3686_CR33","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1172\/JCI88936","volume":"127","author":"KE Elagib","year":"2017","unstructured":"Elagib KE, et al. Neonatal expression of RNA-binding protein IGF2BP3 regulates the human fetal-adult megakaryocyte transition. J Clin Investig. 2017;127(6):2365\u201377.","journal-title":"J Clin Investig"},{"key":"3686_CR34","doi-asserted-by":"publisher","first-page":"154299","DOI":"10.1016\/j.phymed.2022.154299","volume":"104","author":"Y Cui","year":"2022","unstructured":"Cui Y, et al. Isoliquiritigenin inhibits non-small cell lung cancer progression via m6A\/IGF2BP3-dependent TWIST1 mRNA stabilization. Phytomedicine: Int J Phytotherapy Phytopharmacology. 2022;104:154299.","journal-title":"Phytomedicine: Int J Phytotherapy Phytopharmacology"},{"issue":"1","key":"3686_CR35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40364-023-00499-0","volume":"11","author":"T-Y Zhu","year":"2023","unstructured":"Zhu T-Y, Hong L-L, Ling Z-Q. Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential. Biomark Res. 2023;11(1):62.","journal-title":"Biomark Res"},{"key":"3686_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.sbi.2015.01.002","volume":"30","author":"G Nicastro","year":"2015","unstructured":"Nicastro G, Taylor IA, Ramos A. KH-RNA interactions: back in the groove. Curr Opin Struct Biol. 2015;30:63\u201370.","journal-title":"Curr Opin Struct Biol"},{"key":"3686_CR37","doi-asserted-by":"crossref","unstructured":"Bouyahya A, et al. Natural sources, biological effects, and pharmacological properties of cynaroside. Biomedicine & Pharmacotherapy\u2009=\u2009Biomedecine & Pharmacotherapie; 2023. vol. 161: p. 114337.","DOI":"10.1016\/j.biopha.2023.114337"},{"key":"3686_CR38","doi-asserted-by":"crossref","unstructured":"Lei S et al. Cynaroside Induces G1 Cell Cycle Arrest by Downregulating Cell Division Cycle 25A in Colorectal Cancer. Molecules (Basel, Switzerland). 2024;29(7):1508.","DOI":"10.3390\/molecules29071508"},{"key":"3686_CR39","doi-asserted-by":"crossref","unstructured":"Ji J et al. Effects of cynaroside on cell proliferation, apoptosis, migration and invasion though the MET\/AKT\/mTOR Axis in Gastric Cancer. Int J Mol Sci. 2021;22(22):12125.","DOI":"10.3390\/ijms222212125"},{"issue":"6","key":"3686_CR40","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1007\/s10637-021-01148-9","volume":"39","author":"Q-Y Du","year":"2021","unstructured":"Du Q-Y, Zhu Z-M, Pei D-S. The biological function of IGF2BPs and their role in tumorigenesis. Investig New Drugs. 2021;39(6):1682\u201393.","journal-title":"Investig New Drugs"},{"key":"3686_CR41","doi-asserted-by":"crossref","unstructured":"Xia T et al. IGF2BP2 Drives cell cycle progression in triple-negative breast cancer by recruiting EIF4A1 to promote the m6A-Modified CDK6 translation initiation process. advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. 11(1): p. e2305142.","DOI":"10.1002\/advs.202305142"},{"issue":"5","key":"3686_CR42","doi-asserted-by":"publisher","first-page":"e961","DOI":"10.1016\/j.clbc.2018.04.021","volume":"18","author":"H-F Gao","year":"2018","unstructured":"Gao H-F, et al. Prognostic significance of mesenchymal-epithelial transition in triple-negative breast cancers. clin breast cancer. 2018;18(5):e961\u20136.","journal-title":"Clin Breast Cancer"},{"issue":"7","key":"3686_CR43","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S1470-2045(09)70137-8","volume":"10","author":"MV Karamouzis","year":"2009","unstructured":"Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol. 2009;10(7):709\u201317.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3686_CR44","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40265-021-01561-7","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed YY. Amivantamab: first approval. Drugs. 2021;81(11):1349\u201353.","journal-title":"Drugs"},{"issue":"2","key":"3686_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","volume":"24","author":"BC Cho","year":"2023","unstructured":"Cho BC, et al. Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications. Clin Lung Cancer. 2023;24(2):89\u201397.","journal-title":"Clin Lung Cancer"},{"issue":"9","key":"3686_CR46","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1631\/jzus.B2300691","volume":"25","author":"H Zou","year":"2024","unstructured":"Zou H, et al. Cynaroside regulates the AMPK\/SIRT3\/Nrf2 pathway to inhibit doxorubicin-induced cardiomyocyte pyroptosis. J Zhejiang Univ Sci B. 2024;25(9):756\u201372.","journal-title":"J Zhejiang Univ Sci B"},{"key":"3686_CR47","doi-asserted-by":"publisher","first-page":"1405084","DOI":"10.3389\/fimmu.2024.1405084","volume":"15","author":"W Lang","year":"2024","unstructured":"Lang W, et al. Cynaroside ameliorates methotrexate-induced enteritis in rats through inhibiting NLRP3 inflammasome activation. Front Immunol. 2024;15:1405084.","journal-title":"Front Immunol"},{"issue":"35","key":"3686_CR48","doi-asserted-by":"publisher","first-page":"7700","DOI":"10.1021\/jf505848z","volume":"63","author":"L-C Lin","year":"2015","unstructured":"Lin L-C, Pai Y-F, Tsai T-H. Isolation of luteolin and luteolin-7-O-glucoside from dendranthema morifolium ramat Tzvel and their pharmacokinetics in rats. J Agric Food Chem. 2015;63(35):7700\u20136.","journal-title":"J Agric Food Chem"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03686-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03686-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03686-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:57:30Z","timestamp":1781639850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03686-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3686"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03686-7","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TNBC patients tissue samples were collected after surgery from Jiangsu Breast Disease Center, the First Affiliated Hospital with Nanjing Medical University. Such conducts were reviewed and permitted by the Institutional Ethics Committee of the First Affiliated Hospital of Nanjing Medical University (2024-SR-582). Moreover, all experiments involving animals were approved by the Animal Ethics Committee of Nanjing Medical University (IACUC-2206017).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All clinical specimens were collected and used with the patients\u2019 informed consent, and the patients have agreed to their use for research and publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}